Beckman Coulter Developing NSCLC Companion Dx for Transgene | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – French biopharmaceutical firm Transgene today announced Beckman Coulter will develop a companion diagnostic for Transgene to measure levels of activated Natural Killer (aKN) cells so that patients can be selected for treatment with an immunotherapy candidate for non-small cell lung cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Nature News explores the president's "science legacy."

In PLOS this week: genetic factors associated with facial features, a new mutation that makes individuals more prone to Brugada syndrome, and more.

Nutrigenomic companies offer gene-based diet advice, the Wall Street Journal reports.

Researchers have found a new kind of virus — one that starts out broken up into five parts.